Precision glucocorticoid dosing remains investigational; genetic markers not yet clinically actionableNew research explores personalized dosing for steroid medications
Frontiers in MedicinePublished August 25, 2026Study authors: Matteo Colina, Gabriele CampanaDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret pharmacogenomic testing for glucocorticoids as investigational; continue empirical dosing.
This guideline review synthesizes current evidence on precision glucocorticoid pharmacotherapy for patients with immune-mediated diseases, including respiratory, rheumatologic, and inflammatory bowel conditions. The authors propose integrating pharmacogenomics, pharmacokinetic modeling, and biomarker-guided approaches to move beyond empirical dosing. However, they emphasize that this framework remains largely investigational and not yet ready for routine clinical use.
Key findings include suggested associations between genetic variants in NR3C1, FKBP5, CYP3A4/5, and ABCB1 and treatment response or adverse effects. Despite these associations, none of these markers are acknowledged as clinically actionable by consensus resources. The review also discusses risk stratification for glucocorticoid-induced osteoporosis and individualized dose optimization using biomarkers such as eosinophil counts and inflammatory cytokines.
The authors note that routine clinical practice continues to rely predominantly on indication-specific regimens and empirical tapering protocols. The precision framework is described as aspirational, with low certainty regarding its immediate applicability. Limitations include the lack of validated biomarkers and the need for further research to establish clinical utility.
For clinicians, this review provides a research agenda rather than immediate practice changes. While the concept of individualized glucocorticoid therapy is promising, current evidence does not support altering prescribing based on pharmacogenomic testing. Clinicians should continue to use established dosing strategies while staying informed about emerging precision medicine approaches.
How this fits prior evidence
This guideline review extends prior coverage on personalized approaches in immune-mediated diseases. It aligns with the nutrition phenotype framework for IBD and the chemokine network target in lupus nephritis, both of which propose individualized strategies. However, it contrasts with the finding that autoantibody-stratified DMARD selection does not improve RA outcomes, suggesting that not all precision approaches yield clinical benefit. The review addresses a gap by focusing on glucocorticoid pharmacogenomics, but notes that markers are not yet actionable, similar to the limited long-term data for GLP-1 receptor agonists in IBD.
Many people with inflammatory conditions, like rheumatoid arthritis or inflammatory bowel disease, rely on glucocorticoids (steroids) to manage their symptoms. Currently, doctors usually prescribe these based on general guidelines rather than a patient's specific biology. This means some patients might get too much medication, while others may not get enough to feel better.
Researchers are exploring "precision pharmacotherapy" to change this. They looked at how certain genes and biomarkers—like eosinophil counts or inflammatory cytokines—might help doctors predict how a person will respond to steroids. The goal is to move away from one-size-fits-all dosing toward a plan tailored to each individual's unique genetic makeup.
While the science shows that certain genetic variants are linked to treatment response and side effects, these markers are not yet ready for everyday use in clinics. The precision framework is still in the early stages of research. For now, doctors continue to use standard tapering protocols while they work toward more personalized ways to manage these treatments.
What this means for you:
Genetic testing could one day help tailor steroid doses, but this approach is currently in the research phase.
Common questions
How is this different from current treatment?
Currently, most doctors use empirical dosing, which means they follow standard protocols based on the specific disease. The new approach aims to use precision medicine, including pharmacogenomics and biomarker-guided methods, to tailor the dose specifically to a patient's unique biology instead of using a general plan.
Can doctors use these genetic tests right now?
Not yet. While researchers have found that certain genes like NR3C1 and CYP3A4/5 are linked to how patients respond to steroids, these markers are not currently considered clinically actionable by consensus resources. The precision framework is still considered investigational.
What specific conditions does this research focus on?
The research looks at glucocorticoid therapy for several conditions, including respiratory diseases, rheumatologic conditions, inflammatory bowel disease, polymyalgia rheumatica, and critical illness. These are all conditions where steroids are often used to manage inflammation.
Glucocorticoids remain among the most widely prescribed immunosuppressive and anti-inflammatory agents worldwide, yet their clinical use is complicated by substantial inter-individual variability in both therapeutic response and adverse effects. Despite decades of clinical experience, glucocorticoid prescribing remains largely empirical, with limited integration of precision medicine approaches that could optimize therapeutic outcomes while minimizing toxicity. This review synthesizes current evidence on emerging precision approaches to glucocorticoid therapy across three key domains: pharmacogenomic determinants (including variants in NR3C1, FKBP5, CYP3A4/5, and ABCB1) that modulate immune cell responsiveness to glucocorticoids; pharmacokinetic variability and model-informed precision dosing strategies; and disease-specific biomarker-guided approaches across major immune-mediated conditions including respiratory diseases, rheumatologic conditions, inflammatory bowel disease, polymyalgia rheumatica, and critical illness. Genetic variants in glucocorticoid receptor signaling and drug metabolism pathways have suggested some associations with treatment response and adverse effects, although none are yet acknowledged as clinically actionable by consensus resources. Disease-specific immunological biomarkers including eosinophil counts, inflammatory cytokines, and pharmacodynamic endpoints suggest the promise of individualized dose optimization. Risk stratification for glucocorticoid-induced osteoporosis—mediated through OPG/RANKL signaling and monocyte-osteoclast crosstalk—incorporating both clinical factors and pharmacogenetic markers may facilitate targeted prevention strategies. The integration of pharmacogenomic testing, immune biomarker monitoring, and pharmacokinetic modeling represents an aspirational paradigm shift from empirical dosing to individualized immunomodulatory therapy. It should be acknowledged that, as of the time of writing, this precision framework remains largely investigational: routine clinical practice continues to rely predominantly on indication-specific regimens and empirical tapering protocols. This review is explicitly forward-looking, aiming to outline a research agenda for precision glucocorticoid therapy in immune-mediated diseases.
